Skip to main content
Harm Reduction· Article

An 81-Year-Old Is Paying for Test Strips Out of Her Social Security. Washington Calls That Realignment.

Seven months after SAMHSA told grantees they can't buy the strips, the cost has landed on volunteers, retirees, and the people the strips were for.

ByThe Rize NewsroomNovember 10, 202610 min readNovel & Emerging Psychoactives

Diannee Carden Glenn is 81 years old, and she runs an overdose-prevention group out of Greenville, North Carolina, with volunteers and not much else. For about a decade, roughly $15,000 a year from SAMHSA bought the drug test strips her group hands out. Now the money is gone, and the strips are not. “Well, I’m 81 years old, and I get Social Security,” she told KFF Health News when asked how she is paying. That is the funding mechanism now: a retirement check and the occasional donation.

SAMHSA just made it cheaper to die than to know what you are dying from, and called it a realignment.

That is the whole story in one sentence, and the rest of this piece is the receipts. A strip costs about a dollar. It tells you whether fentanyl, or xylazine, or medetomidine is in what you are about to take, before it is in you. In April, the federal agency whose grants had paid for strips like these told its grantees to stop. What follows is what that looks like in a county with no spare money and one 81-year-old.

A dollar item became a retirement-income problem

Start with the arithmetic, because it is small enough to be insulting. Strips run about $1 each, and some groups give out several hundred a week. A grant of $15,000 is not a budget anyone builds a career on. It is the kind of money that disappears into a rounding line at a state agency and reappears, in a place like Greenville, as the difference between a person knowing and a person guessing.

In North Carolina, SAMHSA had been the exclusive source of fentanyl and xylazine strips for the state’s opioid response program, according to KFF Health News. The April letter was part of a reduction of more than $300 million in federal overdose prevention and treatment money. Kentucky shows the scale at the other end of the dial. Shreeta Waldon, who runs the Kentucky Harm Reduction Coalition, told CBS News that her group was losing a $400,000 grant, had distributed 48,465 test strips in the first quarter of the 2026 fiscal year, and had about a month’s supply left. “It doesn’t make sense that one day something is an evidence-based protocol,” Waldon said, and the sentence is worth finishing in your head: and the next day it is a violation.

Put those two numbers next to each other. One group had $15,000 and an 81-year-old. The other had $400,000 and a staff. The policy treats them identically, and the strips they hand out are the same strips. What differs is who can absorb the hit. A volunteer on Social Security can absorb it for a while. Then she cannot, and the people who walk up to her table are the ones who find out how long “a while” was.

The price problem is also getting worse as the drug supply gets stranger. The UNC Street Drug Analysis Lab, which tests what people actually bring in, reports that medetomidine strips run about $200 for a box of 100, against about $35 for fentanyl strips. Medetomidine is a veterinary sedative that now turns up in the street supply more often than xylazine does. So the newest threat has the most expensive detection tool, and the agency that could have helped defray the cost has written a letter saying it will not.

The letter reversed itself, and the people on the ground noticed

You can date the change to the day. On July 30, 2025, SAMHSA sent grantees a Dear Colleague letter responding to the White House order signed that month. That letter listed test strips as a tool SAMHSA money could still support. The order itself, titled “Ending Crime and Disorder on America’s Streets,” says federal grants cannot fund programs that “only facilitate illegal drug use.” Test strips, in the first reading, passed that test. In April 2026 a second letter reversed the first.

That letter listed test strips as a tool SAMHSA money could still support.

CBS News, which reviewed the April letter, reported that agency funding can no longer buy test strips for fentanyl, xylazine, medetomidine, or other adulterants. An HHS spokesperson told CBS the letter “clarifies guidance” and reflects a shift away from “practices that facilitate illicit drug use,” while SAMHSA still prioritizes naloxone. The same spokesperson, in later reporting by NPR, said federal money can still buy strips for police and health workers, but not for the people who use drugs.

Sit with that distinction, because it is the whole policy. A strip in a police evidence kit is a tool. The same strip in the hand of the person who is about to take the drug is a “facilitation.” Maritza Perez Medina, who directs federal policy at the Drug Policy Alliance, told CBS the move left people “just astonished.” A’zhane Powell, who founded Fyrebird Recovery in South Carolina, lost a $4,000 grant and asked the question that matters to anyone who has watched policy swing: “How far will it go until we’re back to square one again?”

If you have ever dipped a strip before you used, you already know what it does and does not do. It does not make the night safe. It gives you one fact you did not have, and what you do with the fact is still yours. That is what the agency declined to pay for. It decided the fact was the problem.

Here is the part the funding story tends to skip. The letter binds SAMHSA grantees. It does not make the strips illegal, and they are not treated as drug paraphernalia in 45 states and Washington, D.C. The strips are still for sale and still lawful across most of the country. What changed is who pays, and whether the person at the table in Greenville can keep paying. Senator Ed Markey and four colleagues, joined by 16 House members, wrote SAMHSA in May saying the directive defies the evidence. “To abandon harm reduction is to do so at our own peril,” Markey wrote. As of the KFF Health News report on November 9, no reversal had been reported.

We have watched Washington decide that a cheap thing that keeps people alive sends the wrong message

This is not new, and the people who lived through the last time recognize the shape of it. In 1988, led by Senator Jesse Helms of North Carolina, Congress barred federal funds for syringe exchange programs, the public health response to HIV among people who inject. The ban held until 2009, when Congress lifted it. In 2011 Congress put it back. Another partial lift came in the December 2015 spending package, which still did not allow federal money to buy syringes. That is more than two decades of fighting over a cheap object, with the dead counted in the meantime.

The pattern repeats because the argument is never about the object. A syringe, a strip, a naloxone kit: each is a few dollars and each tells the person holding it something true. The objection is never that the thing fails to work. The objection is that working, in front of the public, looks like approval. Every generation of this argument ends with the same reversal, and every reversal arrives after a body count nobody asked to be part of. The strip fight is the 1988 fight with a newer chemistry. The lesson was already paid for.

I am not saying the people who wrote the April letter want anyone to die. I am saying we already know how this ends when the cheap, unglamorous tool gets defunded on principle, and the principle was tested for 21 years and lost.

What the strip actually finds, and who finds it

It is easy to hear “test strips” and picture one test for one drug. The reality in a lab in Chapel Hill is more unsettling. Nabarun Dasgupta runs UNC’s Street Drug Analysis Lab, and he calls local drug-checking efforts “engines of ingenuity”. His lab has identified about 500 unique substances since 2022, including levamisole in Edgecombe County and an industrial chemical, BTMPS, in Asheville. Pearson Ripley of Steady Collective in Asheville told KFF Health News the number of substances in the supply rises every year. This is a supply that changes faster than any single strip can track, which is exactly why the volunteers who stand at the tables matter more, not less.

His lab has identified about 500 unique substances since 2022, including levamisole in Edgecombe County and an industrial chemical, BTMPS, in Asheville.

Kaya Littleturtle, who manages programs at the Good Mind Initiative serving Indigenous communities in the Carolinas, put it plainly: “It’s just a hard time right now, because of politics, and politics should never get in the way of saving lives.” That organization holds monthly socials for up to 300 people. Those gatherings are where a strip becomes something other than a strip: it becomes a reason to show up, a thing someone hands you without a lecture.

The federal numbers that justify the cut are real, and they are moving in the right direction. About 68,000 people died of overdose in the 12 months ending November 2025, down from about 111,000 in 2023. The people closest to the work know why that matters and why it can reverse. Arizona offers the warning. Arizona’s overdose deaths ran about 2,800 in the 12 months ending May 2026, near a record, while national deaths dropped sharply, according to provisional CDC data cited by the Tucson Spotlight. A decline at the national level is not a decline in your county.

The doors that are still open, and the one move for your team this week

If you use, or love someone who does, here is what is still yours. Naloxone has been sold over the counter nationwide since March 2023, and HHS says it remains a funding priority. Eli Joy, a peer support specialist at CODAC Health, Recovery and Wellness in Tucson who is in recovery himself, told the Tucson Spotlight naloxone saved his life: “It saved my life.” The SAMHSA National Helpline, 1-800-662-4357, still answers at any hour. And the strips themselves are still lawful to buy and to hold in most of the country, even where no grant pays for them.

For providers and harm reduction programs, the move this week is not complicated, and it is not “raising it with partners.” Pull your grant budget and find every line that pays for test strips. If a SAMHSA dollar is on it, the letter applies to that line. Move the purchase to a non-SAMHSA source: state funds, private donations, or, where your state allows, opioid settlement money. Before you reallocate settlement dollars, get your state fund administrator’s answer in writing about whether strips are an allowable use. Then put the answer in the file, so the next audit finds a document and not a debate.

The people who will tell you this works are not the officials. They are the ones standing at a table in Durham on a Friday, with a spectrometer and a church basement, telling a stranger what is in what they have. Margaret Bordeaux, a longtime harm reduction advocate, told KFF Health News, “I know exactly what happens when those resources aren’t available in communities.” We have run this experiment before. Diannee Carden Glenn is 81, she has her Social Security check, and as long as the check lasts, a stranger in Greenville will know what is in the bag. What happens when it runs out is a question the agency can answer now, or the county will answer later.

Related: Before the Senate Votes on SAMHSA’s Next Chief, Someone Should Ask About Test Strips. More in Harm Reduction and novel and emerging substances.

Filed Under

policyharm-reductionsocial-culturalMedetomidineXylazineSAMHSA

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section